In a series of astonishing admissions, Pfizer CEO Albert Bourla acknowledged during a round of interviews Monday two doses of the company’s COVID vaccine offers “very limited, if any protection.”
Bourla also announced its new COVID vaccine will launch in March tailored to the up-and-coming Omircon variant that Americans no doubt will be mandated to take, and a series of deals centered around altering human DNA — something once deemed an “unhinged conspiracy theory” by the corporate media.
Bourla told CNBC in an interview the company will soon be ready to distribute its new vaccine tailored to the Omicron variant, and have already started “manufacturing some of these quantities at risk.”
“The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose,” Bourla said.
New data from the UK Health and Securty Agency shows Pfizer and Moderna’s vaccines are only about 10% effective at preventing symptomatic infection from Omicron 20 weeks after the second dose.
Pfizer plans to use mRNA technology to alter human DNA
Bourla appeared on Squawk Box earlier Monday after the company announced several agreements in the field of gene editing, with the intent to use these technologies to boost the mRNA platform for their billion-dollar COVID vaccines.
One agreement involves paying $1.35 billion to a company called Beam Therapeutics Inc. to partner on a technique for editing DNA. Two other deals will give the pharma giant access to technology for synthesizing genetic material and delivering it to cells.
Pfizer and Beam plan to use mRNA technology to deliver edits that, if successful, would change a person’s DNA — and if it’s not, will undoubtedly leave many dead or disabled.
Pfizer claims the goal of its new endeavor is to “fix or possibly even cure genetic disease,” although there are many who wish Pfizer would fix or address the adverse events caused by their current mRNA vaccines.
The deals were announced on the first day of the J.P. Morgan Healthcare Conference and highlighted Pfizer’s plans for other mRNA and genetic products.